The 1st Hospital of Hebei Medical University
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Xueyi
NCT04693351 / 2020-004653-69: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Active, not recruiting
3
700
Europe, Canada, US, RoW
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
04/25
04/25
NCT06103825: A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea (OSA)

Recruiting
3
204
RoW
Solriamfetol, Placebo
Ignis Therapeutics (Suzhou) Limited
Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea
09/24
10/24
NCT06259526: A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

Recruiting
2
260
RoW
Placebo group, JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 low-dose group, JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 pills; JS1-1-01 placebo pills, JS1-1-01 high-dose group, JS1-1-01 pills; Duloxetine hydrochloride placebo capsules, Active drug group, JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule
Tasly Pharmaceutical Group Co., Ltd
Depression
04/25
04/25

Download Options